FDA reports more hospitalizations linked to Diamond Shruumz recall

More illnesses and hospitalizations have been linked to recalled mushroom micro-dosing candies, the U.S. Food and Drug Administration (FDA) said on Thursday. As part of an ongoing investigation, the agency also shared new test results revealing what compounds the tested products contain.
The FDA issued an initial warning on June 7, saying a ‘severe’ illness associated with some Diamond Shruumz Microdosing Mushroom Chocolate Bars had landed several people in the hospital suffering medical issues, including seizures, vomiting, and abnormal heart rate.
Originally, the FDA, in tandem with the Centers for Disease Control and America’s Poison Centers and state and local partners, said it was investigating eight illnesses reported from four states, six of which landed people in the hospital. More products were then added to the recall list beyond just chocolate bars.
In a late July update, the agency had tracked 74 cases in 28 states linked to the edibles, resulting in 38 hospitalizations and two potentially associated deaths.
On Thursday, the FDA released the first round of lab results from testing done on different Diamond Shruumz chocolate bars, revealing that some of the products contained prescription or controlled substances and unlisted compounds.
The announcement also confirmed that, as of Aug. 2, the total number of reported illnesses linked to the micro-dosing sweets was up to 113 total with 42 hospitalizations and still two potentially associated deaths across 28 states.
Despite this warning, the products have still been found on shelves in some areas.
Recalls:More cases, additional death reported in nationwide Boar’s Head deli meat listeria outbreak
The ongoing FDA investigation has honed in on discerning what ingredients are causing people to fall ill.
Typically, mushroom-infused products are advertised for use in micro-dosing and often boast the inclusion of “mushroom nootropics” or “functional mushrooms,” which are advertised as being good for brain health and clarity along with offering nutritional value. These claims have not been reviewed by the FDA or other health agencies.
Commercial mushroom-infused products that are sold legally in the U.S. are not supposed to contain what many people traditionally associate with “magic mushrooms.” Instead, they are generally made with extracts from legal mushrooms, such as Amanita muscaria (which produces muscimol), or simply with a “proprietary mushroom blend” that is not fully disclosed on the packaging.
Diamond Shruumz products employ this vague labeling, listing the ingredients as soy, milk, and Diamond’s “proprietary blend of nootropic and functional mushrooms,” according to the company’s website.
Initial FDA lab testing was conducted on 19 samples of Diamon Shruumz Chocolate Bars, six of which were found to contain muscimol. However, the FDA noted that muscimol did not appear in all products and could not “explain all the symptoms reported by ill patients who consumed the Diamond Shruumz-brand Chocolate Bars.”
The testing also found several other compounds in the tested chocolate products, including:
Results shared by the FDA showed varying compounds present not only in different flavors of the chocolate bars but also within the same flavors. The agency noted that there may be variants in which compounds are present and in which combinations are used from product to product.
“Although these compounds individually have known effects when ingested, there is less research on the interactions between these compounds when ingested together,” the FDA said.
The FDA results are consistent with prior testing done by experts at the University of Virginia’s (UVA) poison center in July, which found tested Diamond Shruumz products, along with other mushroom-infused edible brands, contained psilocin.
All Diamond Shruumz-brand Microdosing sweets are included in the FDA recall, including Diamond Shruumz-brand Chocolate Bars, Cones, and Gummies. 
All types of Diamond Shruumz Chocolate Bars and Gummies come in various quantities and flavors, and all flavors of Diamond Shruumz Cones are also covered by the warning.
In a recall notice posted on Diamond Shruumz’s website, parent company Prophet Premium Blends said it had stopped making and distributing all Diamond Shruumz products.
The notice attributed consumer illnesses to higher levels of Muscimol than normal and said it is “crucial” that all consumers “refrain from ingesting this product while we, alongside the FDA, continue our investigation as to what is the cause of the serious adverse effects.”
The FDA has reported cases of illness linked to Diamond Shruumz products in 28 states.
While health agencies continue to search for the cause, people who became ill after eating the product reported several symptoms including:
The FDA advises safely disposing of any Diamond Shruumz-brand products. Consumers who may have the products in their homes should immediately discard them if found. Diamond Shruumz products should not be eaten, sold, or served.
Prophet Premium Blends likewise has advised that no one consumes or sells the products. Retailers and wholesalers should discontinue use, stop distribution, quarantine the product immediately and contact their sales representative to initiate the return and refund. Consumers who have purchased Diamond Shruumz products are urged to stop using the product and return it to 1019 Arlington St., Orlando, FL 32805, for a full refund.